Epigenetic Clinical Trials

2 recruiting

Epigenetic Trials at a Glance

10 actively recruiting trials for epigenetic are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in São Paulo, Guangzhou, and Ljubljana. Lead sponsors running epigenetic studies include Centre Hospitalier Universitaire, Amiens, Federal University of São Paulo, and Benedito Mauro Rossi.

Browse epigenetic trials by phase

Treatments under study

About Epigenetic Clinical Trials

Looking for clinical trials for Epigenetic? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Epigenetic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Epigenetic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Not Applicable

Pesticides and Infertility: Oxidative Stress Via Circulating Cell-free DNA and Gut/Genital Microbiome Signatures in Women With Endometriosis

InfertilityEndometriosisEpigenetics+7 more
Centre Hospitalier Universitaire, Amiens160 enrolled1 locationNCT07471373
Recruiting
Not Applicable

GenoDrugP 2025: Study on Three-dimensional Models Derived From Brain Tumors in Pediatric Patients

EpigeneticPediatric Brain TumorsGenomics
Meyer Children's Hospital IRCCS50 enrolled1 locationNCT07417072
Recruiting

Early Childhood Obesity Programming by Intrauterine Growth Restriction

Childhood ObesityEpigenetics
Montefiore Medical Center400 enrolled1 locationNCT03402139
Recruiting
Phase 2

Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial

ImmunosenescenceEpigenetic Aging
Intervene Immune, Inc.85 enrolled1 locationNCT04375657
Recruiting

Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirPANC 2)

Pancreatic CancerMetastasisEpigenetic
Benedito Mauro Rossi60 enrolled1 locationNCT06945978
Recruiting

Self-harm Behaviour Among the Most At-risk Adolescents

Self-harmEpigenetic DisorderPersonality Disorder, Borderline
University of Ljubljana, Faculty of Medicine400 enrolled2 locationsNCT05765864
Recruiting
Phase 2

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Peripheral T Cell LymphomaEpigenetic Repression
Institute of Hematology & Blood Diseases Hospital, China37 enrolled1 locationNCT05958719
Recruiting
Phase 2

PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)

Coronary DiseaseBleedingCoronary Artery Disease+5 more
Federal University of São Paulo120 enrolled1 locationNCT06542393
Recruiting

Unraveling the Genetic Basis of Nicotine Addiction for Novel Therapeutic Strategies

Smoking CessationEpigeneticsNicotine Addiction+3 more
University of Cyprus200 enrolled1 locationNCT06471387
Recruiting

Offspring Born to Mothers With Polycystic Ovary Syndrome in Guangzhou Cohort Study

Metabolic DisturbanceInsulin ResistanceEpigenetics+4 more
Guangzhou Women and Children's Medical Center2,000 enrolled1 locationNCT03742011